B Seignères1, F Descamps2, R Croise3, V Barlet3, M Bouvier-Alias4, S Chevaliez4, J M Pawlotsky4, W Abdelhady5, M Rafik5, A M Avellon6, J M Echevarria6, M Hausmann7, J-M Dugua7. 1. bioMérieux, R&D Immunoassays, Marcy l'Etoile, France. Electronic address: beatrice.seigneres@biomerieux.com. 2. EFS Nord de France, Lille, France. 3. EFS Rhône-Alpes, Metz-Tessy, France. 4. National Reference Center for Viral Hepatitis B, C and Delta, Department of Virology, Henri Mondor Hospital, Université Paris-Est, INSERM U955, Créteil, France. 5. Clinical Pathology Department, Ain Shams Faculty of Medecine, Cairo, Egypt. 6. National Centre of Microbiology, Department of Virology, Majadahonda, Spain. 7. bioMérieux, R&D Immunoassays, Marcy l'Etoile, France.
Abstract
BACKGROUND: Detection of antibodies (anti-HCV) against hepatitis C virus (HCV) is indispensable for screening and diagnosis of viral hepatitis and for the viral safety of blood, tissue or organ donations. It gains additional importance by the new HCV drugs which improve the therapeutic possibilities dramatically. OBJECTIVE: To evaluate the performance of a newly developed immune assay for anti-HCV based on the well-established VIDAS platform. STUDY DESIGN: The assay was evaluated with samples from anti-HCV negative blood donors and from patients with or without HCV markers in six centres in France, Spain and Egypt. The status of the samples was determined by using CE-marked immune assays (Architect, AxSym, Prism, Vitros), two immunoblots (RIBA, Inno-Lia) and/or HCV RNA results. RESULTS: Specificity was 99.67% in 10,320 French blood donors without anti-HCV, 99.5% in 200 anti-HCV negative hospitalized European patients and 99.0% in 198 negative patients from Egypt. Sensitivity was 99.7% in 1054 patients pretested positive by other assays; 345 patients with known genotype had genotype 1-6; 61 patients were co-infected with HIV. VIDAS was reactive in 78% of 91 patients with uncertain or very weak anti-HCV. It became on average positive at day 37 with seroconversion panels. CONCLUSIONS: This multicentric, international study with >12,000 samples show that the new VIDAS anti-HCV assay is very suitable for screening and confirmation of HCV infection. Sensitivity, specificity and recognition of seroconversion compare favorably with well-established CE-marked tests and help to clarify discrepant results obtained with other assays.
BACKGROUND: Detection of antibodies (anti-HCV) against hepatitis C virus (HCV) is indispensable for screening and diagnosis of viral hepatitis and for the viral safety of blood, tissue or organ donations. It gains additional importance by the new HCV drugs which improve the therapeutic possibilities dramatically. OBJECTIVE: To evaluate the performance of a newly developed immune assay for anti-HCV based on the well-established VIDAS platform. STUDY DESIGN: The assay was evaluated with samples from anti-HCV negative blood donors and from patients with or without HCV markers in six centres in France, Spain and Egypt. The status of the samples was determined by using CE-marked immune assays (Architect, AxSym, Prism, Vitros), two immunoblots (RIBA, Inno-Lia) and/or HCV RNA results. RESULTS: Specificity was 99.67% in 10,320 French blood donors without anti-HCV, 99.5% in 200 anti-HCV negative hospitalized European patients and 99.0% in 198 negative patients from Egypt. Sensitivity was 99.7% in 1054 patients pretested positive by other assays; 345 patients with known genotype had genotype 1-6; 61 patients were co-infected with HIV. VIDAS was reactive in 78% of 91 patients with uncertain or very weak anti-HCV. It became on average positive at day 37 with seroconversion panels. CONCLUSIONS: This multicentric, international study with >12,000 samples show that the new VIDAS anti-HCV assay is very suitable for screening and confirmation of HCV infection. Sensitivity, specificity and recognition of seroconversion compare favorably with well-established CE-marked tests and help to clarify discrepant results obtained with other assays.
Authors: François Cholette; Braedy Farmer; Olga Balakireva; Daria Pavlova; Anna Lopatenko; Iryna Chukhalova; Svitlana Bargan; Sharmistha Mishra; Marissa Becker; Emma R Lee; John Kim; Paul Sandstrom Journal: Sci Rep Date: 2022-06-17 Impact factor: 4.996